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Ebola Virus
• Discovered in 1976 near the Ebola River
in the Democratic Republic of the Congo
• Causes hemorrhagic fever; severe
headache, muscle pain, weakness,
fatigue, diarrhea, vomiting, abdominal
pain, bleeding/bruising
• Spread through direct contact with body
fluids of infected humans/animals
Lancet 1977 309(8011):569-571

• Bats are a likely reservoir of disease
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2014-2016 Outbreak
28,616 Total Cases Reported
in Guinea, Liberia, and Sierra
Leone with 11,310 Deaths as
of 27Mar2016 (latest update)
World Health Organization:
“The 2014–2016 outbreak in West Africa
was the largest and most complex
Ebola outbreak since the virus was first
discovered in 1976.
There were more cases and deaths in
this outbreak than all others combined”
https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/distribution-map.html

4

2014 – 2016 Outbreak

>11X larger than all previous
outbreaks combined
>11k deaths
$2.2B in GDP lost in Guinea,
Liberia, Sierra Leone in 2015

https://www.cdc.gov/vhf/ebola/pdf/impact-ebola-economy.pdf

>$3.6B spent to fight the
epidemic by the end of 2015
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2018 Outbreak
Ebola cases occurred in 2017 and a new
outbreak started in 2018.

http://www.who.int/ebola/situation-reports/drc-2018/en/

World Health Organization:
“Vaccination will be the key to controlling this
outbreak” Dr. Tedros Adhanom Ghebreyesus, WHO
Director General

https://www.cdc.gov/vhf/ebola/outbreaks/drc/drc-map.html
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The Vaccine Candidate: rVSVΔG-ZEBOV-GP (V920)
• A vaccine candidate was developed
• Clinical studies were a global
effort – supported by many
countries and health agencies
• Results from a ring vaccination
trial suggests the V920 vaccine
has high protective efficacy and
effectiveness
• The vaccine was in-licensed by
Merck who took on the responsibility
for research, development, and
manufacturing efforts
https://www.popsci.com/best-of-whats-new-2015/healthcare
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V920 Development at Merck
On Nov 24th 2014 Merck announced an exclusive worldwide agreement with NewLink Genetics to
research, develop, manufacture, distribute, and license V920, an investigational vaccine candidate.
Merck began work on V920 in 2015
• Process Development Scope and Goals:
• Process scale-up in support of Emergency Use and commercial dose production
• Increase lot size from clinical manufacturing scale
• Show comparability between clinical and commercial scale
• Process development and characterization to fully define a robust manufacturing process
• Generate lab-scale data to support process parameter ranges
• Define the Final Manufacturing Process (FMP) Description
• New approaches were needed to accelerate development and characterization work
1. Work in parallel
2. Use a risk-based approach to prioritize development studies
3. Create and use a scale-down model to increase experiment throughput
4. Consider single-use solutions
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V920 Development at Merck
Approach 1: Work in Parallel
• Team 1: Scale-up and emergency use production
• Team 2: Process Development and FMP definition
Approach 2: Use a Risk-Based Approach to Prioritize Experiments; Leverage Existing
Knowledge
Cell Expansion

Unit Operations

Quality Attributes

Plant density
Growth time
Cell passage

Infection and
Harvest

MOI
Plant Density
Time of Infection
Harvest Time

Purification and
Concentration

Filtration loading
Enzyme reaction
TFF

Freeze

• A team of live viral vaccine
SMEs evaluated the clinical
manufacturing process with a
risk assessment to help identify
unit operations and process
parameters in need of study
• Unit operations and parameters
at high risk or with little
understanding were prioritized

Formulation and freeze
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V920 Development at Merck
Approach 3: Develop a Scale-Down Model for experimental work
• Reduced cycle time to generate data
• Reduced from 8+ weeks to 3 weeks

Clinical
Scale-Up
Scale-Down

Log Potency

• Reduced purification process volume from 80L to
1L to enable design of experiments
• Infection – cell/virus interactions
• Purification – enzyme reaction interactions
• Demonstrated comparable to full-scale and
clinical batches
Known
Dilution Effect

Process Step

By the Numbers
• 450+ vials of cells used for lab-scale
experiments
• 200+ experiment notebooks generated and
reviewed
• First draft of FMP issued within 1 year of project
start
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V920 Development at Merck
Multiplicity of Infection (MOI) Robustness

Log Potency

• MOI typically a very sensitive
parameter for infection
• Within our target harvest window a
1000x MOI range is capable of
producing drug substance bulks with
the same range of potencies
• Results in a very robust process and
design space
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V920 Development at Merck
Purification Robustness

Potency Fold Change

• Multifactor DOE performed looking at enzyme
reaction parameters

Potency
increase not
acceptable

• Only the time that the enzyme was added to
reaction was found to be statistically significant
to achieve the desired potency increase
• Failure point used to set PAR
• Tangential Flow Filtration capable of robustly
clearing process residuals with no critical
process parameters

Time Enzyme Added To Reaction

PAR, proven acceptable range
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V920 Development at Merck
Approach 4: Develop a Single-Use Drug Substance Process
•

Desire for modular single-use components with sterile connectors

Month 0-5
• Design and scale-up
• Full scale ENG and
GMP runs

PFD, process flow diagram
URS, user requirement specifications
RFP, request for proposal
VOC, voice of customer

Month 6
• PFD
• URS
• RFP

Month 7
• Initial
Sourcing

Month 10-11
• Layout Study
and functional
evaluation

Layout Study
• Evaluate designs – obtain VOC, to
support component design
simultaneously with operations staff
onboarding and facility retrofit
•

Hands-on training and team building

•

Assembly layout for process and
area fit

•

Began to understand waste streams

VOC, voice of customer
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V920 Development at Merck
Approach 4: Develop a Single-Use Drug Substance Process
•

Desire for modular single-use components with sterile connectors

Month 0-5
• Design and scale-up
• Full scale ENG and
GMP runs

Month 10-13
• Refined
designs with
VOC

PFD, process flow diagram
URS, user requirement specifications
RFP, request for proposal
VOC, voice of customer

Month 6
• PFD
• URS
• RFP

Month 7
• Initial
Sourcing

Month 14
• Signed-off on
last component
• All orders
placed

Month 10-11
• Layout Study
and functional
evaluation

Month 15
• Components start
to be delivered

•

Final process is 100% single-use

•

>500 assemblies made from 42 modular
designs

•

Established a platform approach for
future vaccines

•

Allowed for rapid transfer to the
manufacturing site (15 months)
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Conclusions
Several approaches were used to expedite process development and characterization
of the V920 vaccine candidate and develop a robust process:
1.
2.
3.
4.

Work in parallel
Use a risk-based approach to prioritize development studies
Create and use a scale-down model to increase experiment throughput
Robust Process Results from experiments
1. A 1000x MOI range produces acceptable potencies
2. Enzyme addition is critical for achieving expected potency increase during
purification
3. TFF robustly clears process residuals
5. Consider single-use solutions
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